# Cataya Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cataya-bio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.cataya.com
- Total disclosed funding: $64M
- Latest round: Series B (Sep 4, 2023)
- Investors on record: 7

## About

Established in 2021 and based in Shanghai, China, Ketaiya Biotechnology (Shanghai) Co., Ltd., aka Cataya Bio operates as a synthetic biology company that provides an advanced engineering biology platform and biomanufacturing. The company's team consists of executives from domestic and international synthetic biology leaders Amyris, Plum Bio and Evonik China, etc. Lishan Zhao, the founder and CEO of the company, once served for 14 years at Amyris, a US-based synthetic biology company, as Vice President of research and development and President of China, and he has over two decades of experience in engineering biology.  In January 2026, Cataya Bio raised a venture funding from Zhangjiang Haoheng Capital.

The company uses synthetic biology technology and strain engineering, fermentation and extraction processes and high-throughput automation technologies, etc. to provide natural, green, sustainable and innovative raw material products, including terpenoids, amino acids and their derivatives, and oligosaccharides. It also engages in product development in the fields of personal care, food nutrition and pharmaceutical ingredients.

The company's revenue is generated by providing synthetic biology services.

## Funding rounds

- Series B, Sep 4, 2023, $34M — Eight Roads Ventures, He'nan Investment Group, Bits x Bites, Hengxu Capital
- Series A, Nov 7, 2022, $14M — Eight Roads Ventures, Source Code Capital, HSG, Bits x Bites
- Series A, Jul 1, 2022, $16M — Source Code Capital, Bits x Bites, Sherpa Healthcare Partners

## Investors

- Source Code Capital (https://capitalatlas.ai/funds/source-code-capital) — Series A
- Bits x Bites (https://capitalatlas.ai/funds/bits-x-bites) — Series A, Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A, Series B
- HSG (https://capitalatlas.ai/funds/hsg) — Series A
- He'nan Investment Group (https://capitalatlas.ai/funds/he-nan-investment-group) — Series B
- Hengxu Capital (https://capitalatlas.ai/funds/hengxu-capital) — Series B